Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
ELTX
$9.95
$
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. The company's lead product candidate is ELI-002, an AMP therapeutic vaccine for the treatment of KRAS-driven cancers. It is also developing ELI-004, an AMP-modified CpG adjuvant, a component of ELI-002; ELI-007, a lymph node targeted AMP-peptide vaccine for mutant BRAF-driven cancers; ELI-008, a multivalent lymph node targeted AMP-peptide vaccine for mutant TP53-expressing cancers; ELI-005, a vaccine candidate for the prevention of COVID-19; ELI-011 for the treatment of hematological cancers; and ELI-012, a mKRAS TCR T cell AMP-lifier designs to use in combination with mKRAS-targeted TCR T cell therapy against mKRAS-driven cancers. The company is headquartered in Boston, Massachusetts.
Beta
2.157
Average Volume
Market Cap
Last Dividend
CIK
0001601485
ISIN
US28657F1030
CUSIP
28657F103
CEO
Robert T. Connelly
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
32
IPO Date
2021-02-05
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Elicio Therapeutics Reports Inducement Grants | BOSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on February 17, 2026, Elicio granted an aggregate of 30,300 inducement stock options to a new employee, as an inducement material to such individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. | GlobeNewsWire | 2026-02-18 08:00:00 |
| Elicio Therapeutics Reports Inducement Grants | BOSTON, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on January 15, 2026, Elicio granted an aggregate of 22,400 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. | GlobeNewsWire | 2026-01-16 08:00:00 |
| Elicio Therapeutics Reports Inducement Grants | BOSTON, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on December 15, 2025, Elicio granted an aggregate of 157,193 inducement stock options to three new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio's Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan. | GlobeNewsWire | 2025-12-16 08:00:00 |
| Elicio Therapeutics (ELTX) Upgraded to Buy: Here's Why | Elicio Therapeutics (ELTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). | Zacks Investment Research | 2025-12-11 13:01:25 |
| Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial | Antigen spreading was evaluated in a subset of Phase 2 patients to assess the ability of ELI-002 7P to broaden immune responses to personalized tumor neoantigens not present in the targeted immunotherapy 87% (13/15) of evaluated patients demonstrated induction of T cell responses to tumor neoantigens beyond mKRAS following ELI-002 7P therapy The induction of non-mKRAS antigen-specific T cell responses supports the potential for ELI-002 7P to generate a broader, more adaptable, and personalized anti-tumor response BOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that analysis of a subset of patients in the ongoing Phase 2 AMPLIFY-7P trial has demonstrated that a majority of evaluated patients (13 out of 15) treated with ELI-002 7P induced antigen spreading targeting non-mKRAS neoantigens that are not present in the ELI-002 7P targeted immunotherapy. Consistent with prior observations in Phase 1, treatment with ELI-002 7P in these evaluated patients resulted in T cell responses targeting personalized tumor antigens in addition to responses directed at the driver mKRAS antigens included in the therapy. | GlobeNewsWire | 2025-12-11 08:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2026-02-03 | 2026-02-03 | View Filing |
| 4 | 2025-12-10 | 2025-12-10 | View Filing |
| EFFECT | 2025-12-03 | 2025-12-04 | View Filing |
| S-3 | 2025-11-13 | 2025-11-13 | View Filing |
| 10-Q | 2025-11-13 | 2025-11-13 | View Filing |
| 8-K | 2025-11-13 | 2025-11-13 | View Filing |
| SC 13G/A | 2025-10-07 | 2025-10-07 | View Filing |
| 8-K | 2025-09-17 | 2025-09-17 | View Filing |
| 8-K | 2025-08-12 | 2025-08-12 | View Filing |
| 10-Q | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-07 | 2025-08-07 | View Filing |
| 8-K | 2025-08-05 | 2025-08-05 | View Filing |
| 4 | 2025-06-04 | 2025-06-04 | View Filing |
| SC 13D/A | 2025-06-04 | 2025-06-04 | View Filing |
| 8-K | 2025-06-04 | 2025-06-04 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 4 | 2025-05-20 | 2025-05-20 | View Filing |
| 8-K | 2025-05-20 | 2025-05-20 | View Filing |
| SC 13G/A | 2025-05-14 | 2025-05-14 | View Filing |
| 10-Q | 2025-05-13 | 2025-05-13 | View Filing |
| 8-K | 2025-05-13 | 2025-05-13 | View Filing |
| 4 | 2025-04-16 | 2025-04-16 | View Filing |
| ARS | 2025-04-09 | 2025-04-09 | View Filing |
| DEF 14A | 2025-04-09 | 2025-04-09 | View Filing |
| 3 | 2025-04-02 | 2025-04-02 | View Filing |
| S-8 | 2025-03-31 | 2025-03-31 | View Filing |
| 10-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| SC 13D/A | 2025-03-07 | 2025-03-07 | View Filing |
| 4 | 2025-03-07 | 2025-03-07 | View Filing |
| 8-K | 2025-03-05 | 2025-03-05 | View Filing |
| SC 13G | 2025-02-05 | 2025-02-05 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 4 | 2025-02-04 | 2025-02-04 | View Filing |
| 8-K | 2025-01-30 | 2025-01-30 | View Filing |
| 424B5 | 2025-01-30 | 2025-01-30 | View Filing |
| 8-K | 2025-01-23 | 2025-01-23 | View Filing |
| 8-K | 2025-01-22 | 2025-01-22 | View Filing |
| SC 13G | 2025-01-07 | 2025-01-07 | View Filing |
| 4/A | 2025-01-02 | 2025-01-02 | View Filing |
| 4 | 2024-12-18 | 2024-12-18 | View Filing |
| 8-K | 2024-12-12 | 2024-12-12 | View Filing |
| 8-K | 2024-12-03 | 2024-12-03 | View Filing |
| 4 | 2024-11-29 | 2024-11-29 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 4 | 2024-11-25 | 2024-11-25 | View Filing |
| 424B3 | 2024-11-22 | 2024-11-22 | View Filing |
| 8-K | 2024-11-21 | 2024-11-21 | View Filing |
| EFFECT | 2024-11-21 | 2024-11-21 | View Filing |
| S-3 | 2024-11-13 | 2024-11-13 | View Filing |
| 10-Q | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-13 | 2024-11-13 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-11-07 | 2024-11-07 | View Filing |
| 8-K | 2024-10-17 | 2024-10-17 | View Filing |
| 4 | 2024-10-02 | 2024-10-02 | View Filing |
| 4 | 2024-10-02 | 2024-10-02 | View Filing |
| 4 | 2024-10-02 | 2024-10-02 | View Filing |
| ARS | 2024-09-27 | 2024-09-27 | View Filing |
| DEF 14A | 2024-09-27 | 2024-09-27 | View Filing |
| PRE 14A | 2024-09-17 | 2024-09-17 | View Filing |
| 8-K | 2024-08-30 | 2024-08-30 | View Filing |
| SC 13D/A | 2024-08-14 | 2024-08-14 | View Filing |
| 4 | 2024-08-14 | 2024-08-14 | View Filing |
| 10-Q | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-13 | 2024-08-13 | View Filing |
| 8-K | 2024-08-12 | 2024-08-12 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Williams PercentR Strategy | 28.16% | 1.01 | 265 | 0.04 | 0.09 | 32.22 |
| Bollinger Bands Strategy | 26.50% | 1.06 | 59 | 0.05 | 0.12 | 30.56 |
| Volume Gap | 25.18% | 1 | 608 | 0.02 | 0.05 | 29.24 |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xxx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxx | xxxxxx% | x | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xxx | x | xxxx | xxxx |
| xxxxxxxxx | xxx% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | x | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xxx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xxx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxxx |
| xxxx | xxxxxxxx% | xxxx | xxx | xxxxx | xxxxx | xxxx |